Trusted Resources: Education
Scientific literature and patient education texts
Convergent Molecular Mechanisms Underlying Cognitive Impairment in Mucopolysaccharidosis Type II
source: Metabolic brain disease
year: 2021
authors: Corrêa T,Poswar F,Santos-Rebouças CB
summary/abstract:Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by pathogenic variants in the iduronate-2-sulfatase gene (IDS), responsible for the degradation of glycosaminoglycans (GAGs) heparan and dermatan sulfate. IDS enzyme deficiency results in the accumulation of GAGs within cells and tissues, including the central nervous system (CNS). The progressive neurological outcome in a representative number of MPSII patients (neuronopathic form) involves cognitive impairment, behavioral difficulties, and regression in developmental milestones. In an attempt to dissect part of the influence of axon guidance instability over the cognitive impairment presentation in MPS II, we used brain expression data, network propagation, and clustering algorithm to prioritize in the human interactome a disease module associated with the MPS II context. We identified new candidate genes and pathways that act in focal adhesion, integrin cell surface, laminin interactions, ECM proteoglycans, cytoskeleton, and phagosome that converge into functional mechanisms involved in early neural circuit formation defects and could indicate clues about cognitive impairment in patients with MPSII. Such molecular changes during neurodevelopment may precede the morphological and clinical evidence, emphasizing the importance of an early diagnosis and directing the development of potential drug leads. Furthermore, our data also support previous hypotheses pointing to shared pathogenic mechanisms in some neurodegenerative diseases.
organization: Department of Genetics, Institute of Biosciences, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil. [email protected].
DOI: 10.1007/s11011-021-00872-8
read more
Related Content
-
Mucopolysaccharidosis Type II: A Kenyan Case SeriesHunter syndrome, or mucopolysaccharidosi...
-
Enzyme Replacement Therapy With Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis o...Enzyme replacement therapy (ERT) improve...
-
A Guide to Understanding MPS IIMPS II is a mucopolysaccharide disease k...
-
Hunter Syndrome: OverviewHunter syndrome is a very rare, inherite...
-
Hunter Syndrome – A Rare Genetic DiseaseWhether your son or someone you know has...
-
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...
-
Full Letter From Takeda to the National MPS SocietyOn behalf of Takeda, we are writing to s...